65,437 trials
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines — 23.50; 25.27; 25.29; 24.84 Titer
Migraine With Aura
Primary: Percentage of Participants Experiencing no Pain at Two Hours Post-treatment — 39; 22 percentage of participants
Type Two Diabetes Mellitus
Primary: Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars. — 14.3; 18.4; 16.7 mmol/kg body weight/minute
Fibromyalgia · Sleep Disorders
Primary: Wake After Sleep Onset (WASO) at Weeks 5 and 11 — 70.69; 51.54 Minutes — p=<0.0001
Nasopharyngeal Cancer
Primary: Progression Free Survival. — 6.3 Months
Back Pain
Primary: Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF]) — -1.01; -1.82; -1.92 Units on a scale — p=0.0350
Breast Cancer
Primary: Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery — 15.8; 50.0…
Stomach Neoplasms
Primary: Time to Progression — 4.50; 7.66; 5.55 Months
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Type 2 Diabetes Mellitus
Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml
Ulcerative Colitis
Primary: The Number of Participants With Clinical Response at Week 8 — 44 Participants
Colorectal Cancer · Nausea and Vomiting
Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants
Fever · Sweating · Hot Flashes
Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants
Overweight · Obesity
Primary: Effects on Weight — 93.4; 91.7; 91.9 kilograms
Multiple Sclerosis
Primary: Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector — 89 percentage of participants